Disclosed are compositions, devices, kits, and methods for prevention and/or treatment of Staphylococcus infection. In specific embodiments, Staphylococcus are S. pseudintermedius and/or S. aureus. Aspects of the present disclosure can be directed to bacteriophage compositions comprising one or more of vB_SpsM-DH2, vB_SpsS-DH5, and/or vB_SpsM-DS10. Further disclosed are devices and kits comprising such compositions, and methods for use of such compositions in treatment and prevention of pathogenic Staphylococcus infection.

Disclosed here are bacteriophage compositions for Escherichia comprising CRISPR-Cas systems and methods of use thereof.

Disclosed are isolated bacteriophages having lytic activity against a broad range of mycobacterial species, as well as phage cocktails comprising different mixtures of the isolated bacteriophages. The disclosed bacteriophages include Pill582, and variants thereof, having the ability to stimulate TLR2 signaling and limit intracellular bacterial survival within macrophages through the signalosome involving NLRP3 inflammasome activation leading to the caspase 1 activation and the production of pro-inflammatory cytokine IL-1. Also disclosed are compositions comprising the isolated bacteriophages or phage cocktails, including pharmaceutical compositions and compositions further comprising one or more non-phage therapeutic agents. The disclosed bacteriophage and phage cocktail compositions are useful in methods for treating mycobacterial infections and associated disease conditions.